NASDAQ:NKTR - Nektar Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$79.96 -0.62 (-0.77 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$79.96
Today's Range$79.19 - $81.9550
52-Week Range$17.51 - $111.36
Volume1.75 million shs
Average Volume2.88 million shs
Market Capitalization$14.19 billion
P/E Ratio-145.38
Dividend YieldN/A
Beta1.79

About Nektar Therapeutics (NASDAQ:NKTR)

Nektar Therapeutics logoNektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain based on its PEGylation and polymer conjugate technology platforms in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology. It is also developing MOVANTIK for opioid-induced constipation in adult patients with chronic non-cancer pain, and who have an inadequate response to laxatives; ADYNOVATE for hemophilia A; Somavert to treat acromegaly; and Neulasta for treating neutropenia. In addition, the company develops PEG-INTRON for the treatment of hepatitis-C; Macugen for age-related macular degeneration; CIMZIA to treat rheumatoid arthritis, Crohn's disease, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia related to chronic kidney disease in patients on and not on dialysis. Further, it is developing SEMPRANA to treat migraine; dapirolizumab pegol for systemic lupus erythematosus; PEGPH20 for ancreatic, non-small cell lung cancer, and other tumor types; and longer-acting blood clotting proteins for hemophilia. The company has collaboration agreements with AstraZeneca AB, Shire plc, Pfizer Inc., Amgen Inc., Merck & Co., Inc., Valeant Pharmaceuticals International, Inc., UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Allergan, Inc., Halozyme Therapeutics, Inc., Baxalta Incorporated, and Bristol-Myers Squibb Company. The company was founded in 1990 and is headquartered in San Francisco, California.

Receive NKTR News and Ratings via Email

Sign-up to receive the latest news and ratings for NKTR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:NKTR
CUSIP64026810
Phone415-482-5300

Debt

Debt-to-Equity Ratio4.21
Current Ratio4.16
Quick Ratio4.03

Price-To-Earnings

Trailing P/E Ratio-145.38
Forward P/E Ratio23.66
P/E GrowthN/A

Sales & Book Value

Annual Sales$30.71 million
Price / Sales446.28
Cash FlowN/A
Price / CashN/A
Book Value$0.34 per share
Price / Book235.18

Profitability

EPS (Most Recent Fiscal Year)($0.55)
Net Income$-96,690,000.00
Net Margins-40.07%
Return on Equity-202.41%
Return on Assets-22.92%

Miscellaneous

Employees509
Outstanding Shares171,400,000

Nektar Therapeutics (NASDAQ:NKTR) Frequently Asked Questions

What is Nektar Therapeutics' stock symbol?

Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR."

How were Nektar Therapeutics' earnings last quarter?

Nektar Therapeutics (NASDAQ:NKTR) issued its quarterly earnings data on Thursday, May, 10th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.52) by $0.08. The biopharmaceutical company had revenue of $38.02 million for the quarter, compared to analysts' expectations of $35.59 million. Nektar Therapeutics had a negative net margin of 40.07% and a negative return on equity of 202.41%. The company's revenue for the quarter was up 53.7% on a year-over-year basis. During the same quarter last year, the company earned ($0.42) earnings per share. View Nektar Therapeutics' Earnings History.

When is Nektar Therapeutics' next earnings date?

Nektar Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for Nektar Therapeutics.

What price target have analysts set for NKTR?

12 Wall Street analysts have issued 1-year price targets for Nektar Therapeutics' shares. Their forecasts range from $20.00 to $125.00. On average, they expect Nektar Therapeutics' share price to reach $84.5455 in the next year. View Analyst Ratings for Nektar Therapeutics.

What are Wall Street analysts saying about Nektar Therapeutics stock?

Here are some recent quotes from research analysts about Nektar Therapeutics stock:
  • 1. Mizuho analysts commented, "We believe Keytruda’s data reinforces our thesis on Nektar. Assuming positive data at ASCO, we believe BMS would be inclined to make a bid for Nektar given its deteriorating market position relative to Merck." (4/17/2018)
  • 2. According to Zacks Investment Research, "Nektar has a promising pipeline, with several updates lined up for the next several quarters. Additionally, regular partnerships have enhanced the company’s financial position. Nektar stands to receive significant sales milestone payment plus royalties for Movantik under the license agreement with AstraZeneca. Also, its recent codevelopment deal with Lilly for NKTR-358 is encouraging. On the flip side, Nektar relies heavily on partners for revenues. Partnership-related setbacks may thus weigh heavily on the company, while disappointing products sales could leave an adverse impact on its financial results. Moreover, competition from various pharmaceutical and biotechnology companies is another matter of concern. Shares of the company have significantly outperformed the industry in the last one year." (2/21/2018)

Who are some of Nektar Therapeutics' key competitors?

Who are Nektar Therapeutics' key executives?

Nektar Therapeutics' management team includes the folowing people:
  • Mr. Howard W. Robin, CEO, Pres & Director (Age 65)
  • Mr. Gil M. Labrucherie, Sr. VP & CFO (Age 46)
  • Mr. John Nicholson, Sr. VP & COO (Age 66)
  • Dr. Maninder Hora, Sr. VP of Pharmaceutical Devel. and Chief Technical Operations Officer (Age 64)
  • Ms. Jillian B. Thomsen, Sr. VP of Fin. & Chief Accounting Officer (Age 52)

Has Nektar Therapeutics been receiving favorable news coverage?

News headlines about NKTR stock have been trending somewhat positive this week, according to Accern. Accern identifies negative and positive media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Nektar Therapeutics earned a media sentiment score of 0.12 on Accern's scale. They also gave media coverage about the biopharmaceutical company an impact score of 46.66 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Who are Nektar Therapeutics' major shareholders?

Nektar Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (12.28%), FMR LLC (12.28%), BlackRock Inc. (8.45%), OppenheimerFunds Inc. (6.26%), Northern Trust Corp (1.52%) and JPMorgan Chase & Co. (0.74%). Company insiders that own Nektar Therapeutics stock include Christopher A Kuebler, Gil M Labrucherie, Howard W Robin, Ivan P Gergel, Jillian B Thomsen, John Nicholson, Lutz Lingnau, Maninder Hora, R Scott Greer, Robert Chess, Roy A Whitfield and Stephen K Doberstein. View Institutional Ownership Trends for Nektar Therapeutics.

Which institutional investors are selling Nektar Therapeutics stock?

NKTR stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., OppenheimerFunds Inc., PointState Capital LP, Westfield Capital Management Co. LP, Principal Financial Group Inc., Principal Financial Group Inc., Federated Investors Inc. PA and Public Employees Retirement Association of Colorado. Company insiders that have sold Nektar Therapeutics company stock in the last year include Christopher A Kuebler, Gil M Labrucherie, Howard W Robin, Ivan P Gergel, Jillian B Thomsen, John Nicholson, Lutz Lingnau, Maninder Hora, Robert Chess and Stephen K Doberstein. View Insider Buying and Selling for Nektar Therapeutics.

Which institutional investors are buying Nektar Therapeutics stock?

NKTR stock was acquired by a variety of institutional investors in the last quarter, including Summit Trail Advisors LLC, Northern Trust Corp, Frontier Capital Management Co. LLC, Franklin Resources Inc., Guggenheim Capital LLC, Scout Investments Inc., Schwab Charles Investment Management Inc. and Van ECK Associates Corp. Company insiders that have bought Nektar Therapeutics stock in the last two years include R Scott Greer and Roy A Whitfield. View Insider Buying and Selling for Nektar Therapeutics.

How do I buy shares of Nektar Therapeutics?

Shares of NKTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Nektar Therapeutics' stock price today?

One share of NKTR stock can currently be purchased for approximately $79.96.

How big of a company is Nektar Therapeutics?

Nektar Therapeutics has a market capitalization of $14.19 billion and generates $30.71 million in revenue each year. The biopharmaceutical company earns $-96,690,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis. Nektar Therapeutics employs 509 workers across the globe.

How can I contact Nektar Therapeutics?

Nektar Therapeutics' mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-482-5300 or via email at [email protected]


MarketBeat Community Rating for Nektar Therapeutics (NKTR)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  412 (Vote Outperform)
Underperform Votes:  188 (Vote Underperform)
Total Votes:  600
MarketBeat's community ratings are surveys of what our community members think about Nektar Therapeutics and other stocks. Vote "Outperform" if you believe NKTR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NKTR will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Nektar Therapeutics (NASDAQ:NKTR) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
12 Wall Street analysts have issued ratings and price targets for Nektar Therapeutics in the last 12 months. Their average twelve-month price target is $84.5455, suggesting that the stock has a possible upside of 5.73%. The high price target for NKTR is $125.00 and the low price target for NKTR is $20.00. There are currently 1 hold rating and 11 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.922.922.922.92
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $84.5455$79.75$48.1818$36.6364
Price Target Upside: 5.73% upside10.37% downside36.32% downside18.46% downside

Nektar Therapeutics (NASDAQ:NKTR) Consensus Price Target History

Price Target History for Nektar Therapeutics (NASDAQ:NKTR)

Nektar Therapeutics (NASDAQ:NKTR) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/20/2018HC WainwrightSet Price TargetBuy$125.00LowView Rating Details
5/11/2018Canaccord GenuitySet Price TargetBuy$94.00LowView Rating Details
5/11/2018Piper Jaffray CompaniesSet Price TargetBuy$125.00HighView Rating Details
4/20/2018Seaport Global SecuritiesInitiated CoverageBuy$120.00LowView Rating Details
4/17/2018MizuhoReiterated RatingBuy$103.00LowView Rating Details
3/2/2018CowenReiterated RatingBuy$101.00LowView Rating Details
3/2/2018Jefferies GroupBoost Price TargetBuy$103.00HighView Rating Details
11/13/2017Roth CapitalSet Price TargetBuy$45.00N/AView Rating Details
11/13/2017JPMorgan Chase & Co.Reiterated RatingPositive ➝ Buy$44.00N/AView Rating Details
8/17/2017Evercore ISIInitiated CoverageIn ➝ In-Line$20.00HighView Rating Details
7/18/2017William BlairReiterated RatingOutperformLowView Rating Details
5/10/2017AegisReiterated RatingBuy$27.00HighView Rating Details
3/21/2017BTIG ResearchBoost Price TargetPositive$22.00 ➝ $27.00MediumView Rating Details
9/30/2016Brean CapitalReiterated RatingBuy$23.00N/AView Rating Details
(Data available from 5/25/2016 forward)

Earnings

Nektar Therapeutics (NASDAQ:NKTR) Earnings History and Estimates Chart

Earnings by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Nektar Therapeutics (NASDAQ:NKTR) Earnings Estimates

2018 EPS Consensus Estimate: $2.15
2019 EPS Consensus Estimate: ($3.39)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.32)($0.12)($0.22)
Q2 20183($0.13)$5.66$3.56
Q3 20183($0.72)($0.13)($0.48)
Q4 20182($0.75)($0.67)($0.71)
Q1 20191($0.81)($0.81)($0.81)
Q2 20191($0.83)($0.83)($0.83)
Q3 20191($0.86)($0.86)($0.86)
Q4 20191($0.89)($0.89)($0.89)

Nektar Therapeutics (NASDAQ NKTR) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/6/2018$4.68N/AView Earnings Details
5/10/2018Q1 2018($0.52)($0.60)$35.59 million$38.02 millionViewN/AView Earnings Details
3/1/2018Q4 2017($0.35)($0.21)$36.96 million$95.47 millionViewListenView Earnings Details
11/7/2017Q3 2017$0.21$0.3740$126.50 million$152.90 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.35)($0.39)$33.64 million$34.60 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.40)($0.42)$29.43 million$24.73 millionViewListenView Earnings Details
3/1/2017Q416($0.26)($0.28)$40.83 million$37.45 millionViewListenView Earnings Details
11/3/2016Q316($0.36)($0.32)$32.42 million$36.30 millionViewN/AView Earnings Details
8/3/2016Q216($0.33)($0.36)$34.17 million$32.77 millionViewListenView Earnings Details
5/3/2016Q1($0.23)($0.14)$43.78 million$58.88 millionViewN/AView Earnings Details
3/1/2016Q4($0.42)($0.40)$28.82 million$39.40 millionViewListenView Earnings Details
11/5/2015Q315($0.30)($0.06)$44.30 million$60.00 millionViewN/AView Earnings Details
8/5/2015Q215($0.40)($0.40)$21.49 million$22.66 millionViewN/AView Earnings Details
4/30/2015Q115($0.40)$0.25$20.20 million$108.80 millionViewN/AView Earnings Details
2/24/2015Q414($0.36)($0.35)$12.30 million$19.55 millionViewN/AView Earnings Details
11/6/2014Q314$0.39$0.53$123.20 million$132.90 millionViewN/AView Earnings Details
7/31/2014Q214($0.38)($0.26)$19.76 million$28.50 millionViewListenView Earnings Details
5/7/2014Q114($0.35)($0.37)$38.68 million$19.80 millionViewListenView Earnings Details
2/26/2014Q413($0.17)($0.41)$49.26 million$31.15 millionViewN/AView Earnings Details
11/7/2013Q313($0.22)($0.14)$54.34 million$60.91 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.44)($0.37)$26.22 million$33.86 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.42)($0.48)$26.30 million$23.00 millionViewN/AView Earnings Details
2/28/2013Q4 2012($0.45)($0.46)ViewN/AView Earnings Details
11/9/2012Q312($0.39)($0.38)$21.02 million$18.41 millionViewN/AView Earnings Details
8/9/2012($0.33)($0.30)ViewN/AView Earnings Details
5/2/2012($0.33)($0.36)ViewN/AView Earnings Details
2/29/2012($0.47)($0.33)ViewN/AView Earnings Details
11/2/2011($0.37)($0.21)ViewN/AView Earnings Details
8/4/2011($0.31)($0.32)ViewN/AView Earnings Details
4/27/2011($0.27)($0.33)ViewN/AView Earnings Details
3/1/2011Q4 2010($0.16)($0.11)ViewN/AView Earnings Details
11/4/2010Q3 2010($0.05)($0.09)ViewN/AView Earnings Details
7/28/2010Q2 2010($0.09)($0.01)ViewN/AView Earnings Details
5/5/2010Q1 2010($0.09)($0.07)ViewN/AView Earnings Details
3/2/2010Q4 2009$0.08($0.08)ViewN/AView Earnings Details
11/4/2009Q3 2009($0.40)($0.33)ViewN/AView Earnings Details
8/4/2009Q2 2009($0.42)($0.35)ViewN/AView Earnings Details
5/6/2009Q1 2009($0.41)($0.34)ViewN/AView Earnings Details
2/24/2009Q4 2008($0.31)($0.46)ViewN/AView Earnings Details
11/6/2008Q3 2008($0.29)($0.40)ViewN/AView Earnings Details
8/6/2008Q2 2008($0.31)($0.36)ViewN/AView Earnings Details
5/7/2008Q1 2008($0.27)($0.44)ViewN/AView Earnings Details
2/27/2008Q4 2007($0.25)($0.13)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Nektar Therapeutics (NASDAQ:NKTR) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Nektar Therapeutics (NASDAQ NKTR) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.10%
Institutional Ownership Percentage: 91.03%
Insider Trading History for Nektar Therapeutics (NASDAQ:NKTR)
Institutional Ownership by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Nektar Therapeutics (NASDAQ NKTR) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/16/2018Gil M. LabrucherieCFOSell4,941$83.39$412,029.99View SEC Filing  
5/16/2018Howard W RobinCEOSell12,791$83.39$1,066,641.49224,356View SEC Filing  
5/16/2018Jillian B. ThomsenCAOSell3,576$83.39$298,202.64View SEC Filing  
5/16/2018John NicholsonCOOSell4,917$83.39$410,028.63162,596View SEC Filing  
5/16/2018Stephen K DobersteinSVPSell3,435$83.39$286,444.6563,959View SEC Filing  
5/3/2018Gil M. LabrucherieCFOSell90,000$84.05$7,564,500.00View SEC Filing  
5/3/2018Howard W RobinCEOSell130,000$84.05$10,926,500.00280,481View SEC Filing  
5/3/2018Robert ChessDirectorSell25,000$82.80$2,070,000.00284,223View SEC Filing  
5/1/2018Gil M. LabrucherieCFOSell30,000$83.65$2,509,500.00View SEC Filing  
5/1/2018Howard W RobinCEOSell43,334$83.65$3,624,889.10280,481View SEC Filing  
4/16/2018Jillian B. ThomsenSVPSell13,881$101.46$1,408,366.26View SEC Filing  
4/9/2018Stephen K DobersteinSVPSell160,000$93.06$14,889,600.00127,394View SEC Filing  
4/6/2018Robert ChessDirectorSell25,000$92.14$2,303,500.00284,223View SEC Filing  
4/5/2018Maninder HoraSVPSell20,000$101.75$2,035,000.00127,394View SEC Filing  
3/7/2018Christopher A KueblerDirectorSell40,000$97.60$3,904,000.0043,100View SEC Filing  
3/7/2018John NicholsonCOOSell220,144$99.27$21,853,694.88267,657View SEC Filing  
2/16/2018Gil M. LabrucherieCFOSell3,477$82.94$288,382.38View SEC Filing  
2/16/2018Howard W RobinCEOSell12,788$82.94$1,060,636.72237,147View SEC Filing  
2/16/2018Jillian B. ThomsenCAOSell2,545$82.94$211,082.30View SEC Filing  
2/16/2018John NicholsonCOOSell4,879$82.94$404,664.26387,657View SEC Filing  
2/16/2018Stephen K DobersteinSVPSell2,426$82.94$201,212.4467,394View SEC Filing  
1/22/2018Howard W RobinCEOSell83,333$75.82$6,318,308.06333,268View SEC Filing  
1/2/2018Christopher A KueblerDirectorSell30,000$58.66$1,759,800.0070,500View SEC Filing  
12/13/2017Howard W RobinCEOSell83,333$55.69$4,640,814.77272,768View SEC Filing  
11/13/2017John NicholsonCOOSell15,910$37.78$601,079.80249,066View SEC Filing  
11/8/2017Stephen K DobersteinSVPSell396,323$29.00$11,493,367.0052,016View SEC Filing  
11/6/2017Maninder HoraSVPSell5,117$25.07$128,283.1952,016View SEC Filing  
11/1/2017Howard W RobinCEOSell83,334$23.57$1,964,182.38235,838View SEC Filing  
10/9/2017Howard W RobinCEOSell83,333$24.20$2,016,658.60View SEC Filing  
10/5/2017Stephen K DobersteinSVPSell43,677$24.97$1,090,614.69View SEC Filing  
10/2/2017Gil M. LabrucherieCFOSell120,000$24.45$2,934,000.00View SEC Filing  
10/2/2017Ivan P GergelSVPSell100,000$24.14$2,414,000.0084,871View SEC Filing  
9/22/2017Christopher A KueblerDirectorSell4,000$21.86$87,440.0040,500View SEC Filing  
9/21/2017Robert ChessDirectorSell6,400$21.72$139,008.00274,223View SEC Filing  
9/6/2017Howard W RobinCEOSell83,333$21.54$1,794,992.82235,837View SEC Filing  
8/16/2017Howard W RobinCEOSell91,714$19.26$1,766,411.64152,504View SEC Filing  
8/16/2017Jillian B. ThomsenCAOSell2,648$19.32$51,159.36View SEC Filing  
8/16/2017John NicholsonCOOSell3,177$19.32$61,379.64224,066View SEC Filing  
8/16/2017Stephen K DobersteinSVPSell1,701$19.32$32,863.3231,102View SEC Filing  
8/10/2017Roy A WhitfieldDirectorBuy35,000$17.95$628,250.00133,000View SEC Filing  
7/18/2017Ivan P GergelSVPSell54,920$21.10$1,158,812.0098,492View SEC Filing  
7/14/2017Lutz LingnauDirectorSell30,000$20.76$622,800.0053,450View SEC Filing  
7/12/2017Ivan P GergelSVPSell45,080$21.08$950,286.4051,961View SEC Filing  
7/11/2017Ivan P GergelSVPSell8,389$21.04$176,504.5651,961View SEC Filing  
5/16/2017Gil M. LabrucherieCFOSell3,179$19.55$62,149.45View SEC Filing  
5/16/2017Howard W RobinCEOSell8,388$19.55$163,985.40160,884View SEC Filing  
5/16/2017John NicholsonCOOSell3,146$19.55$61,504.30178,943View SEC Filing  
5/16/2017Stephen K DobersteinSVPSell1,701$19.55$33,254.5532,803View SEC Filing  
5/15/2017Robert ChessDirectorSell5,000$19.79$98,950.00276,623View SEC Filing  
4/17/2017Robert ChessDirectorSell5,000$18.72$93,600.00276,623View SEC Filing  
4/7/2017Lutz LingnauDirectorSell7,000$20.05$140,350.0023,450View SEC Filing  
4/5/2017Christopher A KueblerDirectorSell15,000$21.88$328,200.0050,500View SEC Filing  
4/5/2017Maninder HoraSVPSell180,000$21.70$3,906,000.00View SEC Filing  
3/20/2017Jillian B. ThomsenSVPSell112,500$19.69$2,215,125.00View SEC Filing  
3/3/2017Gil M. LabrucherieCFOSell200,000$15.16$3,032,000.00View SEC Filing  
2/16/2017Gil M. LabrucherieCFOSell2,359$13.14$30,997.26View SEC Filing  
2/16/2017Howard W RobinCEOSell8,636$13.14$113,477.04169,272View SEC Filing  
2/16/2017Ivan P GergelSVPSell1,457$13.14$19,144.9845,022View SEC Filing  
2/16/2017John NicholsonCOOSell3,237$13.14$42,534.18182,089View SEC Filing  
2/8/2017Howard W RobinCEOSell87,500$13.04$1,141,000.00265,408View SEC Filing  
2/3/2017John NicholsonCOOSell75,000$12.39$929,250.00206,821View SEC Filing  
1/17/2017Howard W RobinCEOSell87,500$12.35$1,080,625.00265,408View SEC Filing  
11/17/2016Howard W RobinCEOSell93,458$13.88$1,297,197.04122,908View SEC Filing  
10/24/2016R Scott GreerDirectorBuy15,000$13.50$202,500.00121,333View SEC Filing  
10/4/2016Howard W. RobinCEOSell87,500$17.06$1,492,750.00View SEC Filing  
9/16/2016Christopher A. KueblerDirectorSell7,500$19.13$143,475.00View SEC Filing  
9/15/2016Robert ChessDirectorSell12,000$19.21$230,520.00View SEC Filing  
9/1/2016Howard W. RobinCEOSell87,500$17.83$1,560,125.00View SEC Filing  
8/16/2016Gil M. LabrucherieCFOSell3,305$17.56$58,035.80View SEC Filing  
8/16/2016Howard W. RobinCEOSell11,817$17.56$207,506.52View SEC Filing  
8/16/2016John NicholsonCOOSell3,317$17.56$58,246.52View SEC Filing  
8/16/2016Stephen K. DobersteinSVPSell1,336$17.56$23,460.16View SEC Filing  
8/1/2016Robert ChessDirectorSell5,000$17.26$86,300.00View SEC Filing  
7/11/2016Jillian B ThomsenCAOSell100,000$15.09$1,509,000.00106,809View SEC Filing  
7/1/2016Robert ChessDirectorSell5,000$14.10$70,500.00View SEC Filing  
5/17/2016Gil M LabrucherieSVPSell836$13.58$11,352.888,757View SEC Filing  
5/17/2016Howard W RobinCEOSell2,170$13.58$29,468.6019,103View SEC Filing  
5/17/2016Jillian B ThomsenCAOSell724$13.58$9,831.927,033View SEC Filing  
5/17/2016John NicholsonCFOSell856$13.58$11,624.4878,486View SEC Filing  
4/25/2016Lutz LingnauDirectorSell15,000$16.27$244,050.0031,450View SEC Filing  
2/17/2016Howard W. RobinCEOSell2,147$11.92$25,592.2413,478View SEC Filing  
2/17/2016Jillian B. ThomsenCAOSell716$11.92$8,534.725,158View SEC Filing  
2/17/2016Maninder HoraSVPSell963$11.92$11,478.965,803View SEC Filing  
2/10/2016Gil M. LabrucherieSVPSell11,666$11.49$134,042.345,251View SEC Filing  
2/10/2016Howard W. RobinCEOSell66,666$11.49$765,992.3410,000View SEC Filing  
2/10/2016Jillian B. ThomsenCAOSell15,000$11.49$172,350.003,999View SEC Filing  
1/20/2016Lutz LingnauDirectorSell15,000$14.51$217,650.0016,450View SEC Filing  
1/19/2016Gil M. LabrucherieSVPSell11,667$14.12$164,738.045,251View SEC Filing  
1/19/2016Howard W. RobinCEOSell66,667$14.12$941,338.0410,000View SEC Filing  
1/19/2016Jillian B. ThomsenCAOSell15,000$14.12$211,800.003,999View SEC Filing  
12/4/2015Christopher A. KueblerDirectorSell15,000$15.82$237,300.0020,000View SEC Filing  
12/3/2015Gil M. LabrucherieSVPSell45,001$15.87$714,165.875,251View SEC Filing  
12/3/2015Howard W. RobinCEOSell125,001$15.87$1,983,765.8710,000View SEC Filing  
12/3/2015Jillian B. ThomsenCAOSell15,000$15.87$238,050.003,999View SEC Filing  
11/20/2015Susan WangDirectorSell85,000$15.02$1,276,700.0020,000View SEC Filing  
11/11/2015Gil M. LabrucherieSVPSell45,000$13.52$608,400.004,751View SEC Filing  
11/11/2015Howard W. RobinCEOSell125,000$13.52$1,690,000.0010,000View SEC Filing  
11/11/2015Jillian B. ThomsenCAOSell15,000$13.52$202,800.003,499View SEC Filing  
10/28/2015Lutz LingnauDirectorSell12,500$12.00$150,000.0016,450View SEC Filing  
10/6/2015Gil M. LabrucherieSVPSell45,000$10.99$494,550.004,751View SEC Filing  
10/6/2015Howard W. RobinCEOSell125,000$10.99$1,373,750.0010,000View SEC Filing  
10/6/2015Jillian B. ThomsenCAOSell15,000$10.99$164,850.003,499View SEC Filing  
9/23/2015Gil M. LabrucherieSVPSell44,999$13.04$586,786.964,751View SEC Filing  
9/23/2015Howard W. RobinCEOSell124,999$13.04$1,629,986.9610,000View SEC Filing  
9/23/2015Jillian B. ThomsenCAOSell10,000$13.04$130,400.003,499View SEC Filing  
8/13/2015Gil M LabrucherieSVPSell33,333$10.89$362,996.37View SEC Filing  
8/13/2015Howard W RobinCEOSell58,333$10.89$635,246.37View SEC Filing  
7/14/2015Gil M LabrucherieSVPSell33,334$11.78$392,674.52View SEC Filing  
7/14/2015Howard W RobinCEOSell58,334$11.78$687,174.52View SEC Filing  
6/29/2015Susan WangDirectorSell30,000$12.70$381,000.00View SEC Filing  
6/19/2015Robert ChessDirectorSell15,000$11.81$177,150.00View SEC Filing  
6/15/2015Lutz LingnauDirectorSell25,000$11.15$278,750.00View SEC Filing  
12/29/2014Robert ChessDirectorSell29,500$15.34$452,530.00View SEC Filing  
12/22/2014Jillian B ThomsenCAOSell5,000$15.56$77,800.00View SEC Filing  
12/1/2014Gil M LabrucherieSVPSell120,000$17.02$2,042,400.00View SEC Filing  
12/1/2014Howard W RobinCEOSell350,000$17.01$5,953,500.00View SEC Filing  
11/25/2014Howard W RobinCEOSell600,000$15.25$9,150,000.00View SEC Filing  
11/24/2014Gil M LabrucherieSVPSell10,500$15.04$157,920.00View SEC Filing  
11/24/2014Howard W RobinCEOSell132,800$15.02$1,994,656.00View SEC Filing  
11/24/2014Lutz LingnauDirectorSell15,000$15.02$225,300.00View SEC Filing  
11/3/2014Gil M LabrucherieSVPSell9,900$13.78$136,422.00View SEC Filing  
8/5/2013Roy WhitfieldDirectorSell12,500$12.41$155,125.0020,000View SEC Filing  
9/14/2012Dennis L WingerDirectorBuy5,000$9.18$45,900.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Nektar Therapeutics (NASDAQ NKTR) News Headlines

Source:
DateHeadline
Nektar Therapeutics (NKTR) Expected to Announce Quarterly Sales of $1.04 BillionNektar Therapeutics (NKTR) Expected to Announce Quarterly Sales of $1.04 Billion
www.americanbankingnews.com - May 25 at 2:54 AM
Nektar Therapeutics (NKTR) Expected to Announce Earnings of $5.33 Per ShareNektar Therapeutics (NKTR) Expected to Announce Earnings of $5.33 Per Share
www.americanbankingnews.com - May 23 at 1:27 PM
HC Wainwright Analysts Give Nektar Therapeutics (NKTR) a $125.00 Price TargetHC Wainwright Analysts Give Nektar Therapeutics (NKTR) a $125.00 Price Target
www.americanbankingnews.com - May 21 at 9:14 AM
Jillian B. Thomsen Sells 3,576 Shares of Nektar Therapeutics (NKTR) StockJillian B. Thomsen Sells 3,576 Shares of Nektar Therapeutics (NKTR) Stock
www.americanbankingnews.com - May 18 at 7:53 PM
Nektar Therapeutics (NKTR) SVP Sells $286,444.65 in StockNektar Therapeutics (NKTR) SVP Sells $286,444.65 in Stock
www.americanbankingnews.com - May 18 at 7:53 PM
Nektar Therapeutics (NKTR) CFO Gil M. Labrucherie Sells 4,941 SharesNektar Therapeutics (NKTR) CFO Gil M. Labrucherie Sells 4,941 Shares
www.americanbankingnews.com - May 18 at 7:53 PM
Insider Selling: Nektar Therapeutics (NKTR) COO Sells 4,917 Shares of StockInsider Selling: Nektar Therapeutics (NKTR) COO Sells 4,917 Shares of Stock
www.americanbankingnews.com - May 18 at 7:53 PM
Howard W. Robin Sells 12,791 Shares of Nektar Therapeutics (NKTR) StockHoward W. Robin Sells 12,791 Shares of Nektar Therapeutics (NKTR) Stock
www.americanbankingnews.com - May 18 at 7:37 PM
Seaport Global Securities Weighs in on Nektar Therapeutics Q2 2018 Earnings (NKTR)Seaport Global Securities Weighs in on Nektar Therapeutics' Q2 2018 Earnings (NKTR)
www.americanbankingnews.com - May 18 at 7:12 AM
Here's Why Nektar Therapeutics Fell as Much as 11.1% TodayHere's Why Nektar Therapeutics Fell as Much as 11.1% Today
finance.yahoo.com - May 17 at 3:36 PM
Heres Why Nektar Therapeutics Fell as Much as 11.1% TodayHere's Why Nektar Therapeutics Fell as Much as 11.1% Today
www.fool.com - May 17 at 1:40 PM
BioXcel Therapeutics (BTAI) Announces Data Presentation at ASCOBioXcel Therapeutics (BTAI) Announces Data Presentation at ASCO
www.streetinsider.com - May 17 at 10:46 AM
Nektar Therapeutics: Substantial Unlocked Value In The NKTR-358 FranchiseNektar Therapeutics: Substantial Unlocked Value In The NKTR-358 Franchise
seekingalpha.com - May 16 at 11:06 AM
Q2 2018 Earnings Forecast for Nektar Therapeutics Issued By William Blair (NKTR)Q2 2018 Earnings Forecast for Nektar Therapeutics Issued By William Blair (NKTR)
www.americanbankingnews.com - May 16 at 7:17 AM
Nektar Therapeutics Stock Is Risky But Offers Big RewardNektar Therapeutics Stock Is Risky But Offers Big Reward
investorplace.com - May 15 at 2:34 PM
IWM, NKTR, GRUB, BLUE: Large Inflows Detected at ETFIWM, NKTR, GRUB, BLUE: Large Inflows Detected at ETF
www.nasdaq.com - May 14 at 3:38 PM
Nektar (NKTR) Q1 Loss Wider Than Expected, Sales Soar Y/YNektar (NKTR) Q1 Loss Wider Than Expected, Sales Soar Y/Y
finance.yahoo.com - May 14 at 11:43 AM
Nektar Therapeutics (NKTR) Announces Initiation of a Phase 1b Clinical Study of NKTR-358Nektar Therapeutics (NKTR) Announces Initiation of a Phase 1b Clinical Study of NKTR-358
www.streetinsider.com - May 12 at 11:00 AM
Edited Transcript of NKTR earnings conference call or presentation 10-May-18 9:00pm GMTEdited Transcript of NKTR earnings conference call or presentation 10-May-18 9:00pm GMT
finance.yahoo.com - May 12 at 11:00 AM
Canaccord Genuity Analysts Give Nektar Therapeutics (NKTR) a $94.00 Price TargetCanaccord Genuity Analysts Give Nektar Therapeutics (NKTR) a $94.00 Price Target
www.americanbankingnews.com - May 11 at 6:13 PM
Nektar Therapeutics (NKTR) PT Set at $125.00 by Piper JaffrayNektar Therapeutics (NKTR) PT Set at $125.00 by Piper Jaffray
www.americanbankingnews.com - May 11 at 3:56 PM
Nektar Therapeutics Reports Financial Results for the First Quarter of 2018Nektar Therapeutics Reports Financial Results for the First Quarter of 2018
finance.yahoo.com - May 11 at 11:39 AM
Nektar: 1Q Earnings SnapshotNektar: 1Q Earnings Snapshot
www.foxnews.com - May 11 at 11:39 AM
Nektars (NKTR) CEO Howard Robin on Q1 2018 Results - Earnings Call TranscriptNektar's (NKTR) CEO Howard Robin on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 11 at 11:39 AM
3 Stocks to Watch on Friday: Alphabet Inc (GOOG, GOOGL), Nektar Therapeutics (NKTR) and Solaredge Technologies Inc (SEDG)3 Stocks to Watch on Friday: Alphabet Inc (GOOG, GOOGL), Nektar Therapeutics (NKTR) and Solaredge Technologies Inc (SEDG)
investorplace.com - May 11 at 7:30 AM
Nektar Therapeutics (NKTR) Issues Quarterly  Earnings ResultsNektar Therapeutics (NKTR) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 10 at 7:50 PM
[$$] 100 Days of Volatility: Yes, Its Been That Wild[$$] 100 Days of Volatility: Yes, It's Been That Wild
finance.yahoo.com - May 10 at 10:51 AM
Nektar Therapeutics Announces Initiation of a Phase 1b Clinical Study of NKTR ...Nektar Therapeutics Announces Initiation of a Phase 1b Clinical Study of NKTR ...
www.prnewswire.com - May 9 at 10:35 AM
Nektar Therapeutics Announces Initiation of a Phase 1b Clinical Study of NKTR-358, a First-in-Class Regulatory T Cell Stimulator, in Patients with Systemic Lupus ErythematosusNektar Therapeutics Announces Initiation of a Phase 1b Clinical Study of NKTR-358, a First-in-Class Regulatory T Cell Stimulator, in Patients with Systemic Lupus Erythematosus
finance.yahoo.com - May 8 at 10:22 AM
$46.50 Million in Sales Expected for Nektar Therapeutics (NKTR) This Quarter$46.50 Million in Sales Expected for Nektar Therapeutics (NKTR) This Quarter
www.americanbankingnews.com - May 8 at 4:32 AM
Nektar Therapeutics (NKTR) Given Average Recommendation of "Buy" by BrokeragesNektar Therapeutics (NKTR) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 7 at 9:09 AM
-$0.48 EPS Expected for Nektar Therapeutics (NKTR) This Quarter-$0.48 EPS Expected for Nektar Therapeutics (NKTR) This Quarter
www.americanbankingnews.com - May 6 at 3:14 AM
Robert Chess Sells 25,000 Shares of Nektar Therapeutics (NKTR) StockRobert Chess Sells 25,000 Shares of Nektar Therapeutics (NKTR) Stock
www.americanbankingnews.com - May 4 at 7:34 PM
Form 4 NEKTAR THERAPEUTICS For: May 01 Filed by: Labrucherie Gil MForm 4 NEKTAR THERAPEUTICS For: May 01 Filed by: Labrucherie Gil M
www.streetinsider.com - May 4 at 10:21 AM
Nektar Therapeutics (NKTR) CFO Sells $7,564,500.00 in StockNektar Therapeutics (NKTR) CFO Sells $7,564,500.00 in Stock
www.americanbankingnews.com - May 3 at 10:21 PM
Nektar Therapeutics (NKTR) CEO Howard W. Robin Sells 43,334 SharesNektar Therapeutics (NKTR) CEO Howard W. Robin Sells 43,334 Shares
www.americanbankingnews.com - May 3 at 10:19 PM
Nektar Therapeutics (NKTR) CEO Sells $10,926,500.00 in StockNektar Therapeutics (NKTR) CEO Sells $10,926,500.00 in Stock
www.americanbankingnews.com - May 3 at 10:19 PM
Nektar Therapeutics (NKTR) CFO Gil M. Labrucherie Sells 30,000 SharesNektar Therapeutics (NKTR) CFO Gil M. Labrucherie Sells 30,000 Shares
www.americanbankingnews.com - May 3 at 10:15 PM
Biotech: Nektars Stock May Fall 15% FurtherBiotech: Nektar's Stock May Fall 15% Further
finance.yahoo.com - May 3 at 3:38 PM
Nektar to Announce Financial Results for the First Quarter 2018 on Thursday, May 10, 2018, After Close of U.S.-Based Financial MarketsNektar to Announce Financial Results for the First Quarter 2018 on Thursday, May 10, 2018, After Close of U.S.-Based Financial Markets
finance.yahoo.com - May 3 at 10:22 AM
Nektar Therapeutics (NKTR) Stock Rating Upgraded by ValuEngineNektar Therapeutics (NKTR) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - May 2 at 11:37 PM
Nektar Therapeutics to Host Analyst & Investor Event at 2018 ASCO Annual MeetingNektar Therapeutics to Host Analyst & Investor Event at 2018 ASCO Annual Meeting
finance.yahoo.com - April 30 at 9:46 AM
Nektar Therapeutics (NKTR) Buy Rating Reaffirmed at HC WainwrightNektar Therapeutics' (NKTR) Buy Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - April 30 at 8:56 AM
Nektar Therapeutics (NKTR) Scheduled to Post Earnings on MondayNektar Therapeutics (NKTR) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - April 30 at 8:35 AM
Nektar Therapeutics (NKTR) Downgraded by BidaskClubNektar Therapeutics (NKTR) Downgraded by BidaskClub
www.americanbankingnews.com - April 26 at 1:10 PM
Piper Jaffray Analysts Give Nektar Therapeutics (NKTR) a $125.00 Price TargetPiper Jaffray Analysts Give Nektar Therapeutics (NKTR) a $125.00 Price Target
www.americanbankingnews.com - April 26 at 8:00 AM
Nektar Therapeutics (NKTR) Says Pact With Takeda to Evaluate Combination of ...Nektar Therapeutics (NKTR) Says Pact With Takeda to Evaluate Combination of ...
www.streetinsider.com - April 25 at 10:59 AM
Nektar Enters Into New Clinical Collaboration With TakedaNektar Enters Into New Clinical Collaboration With Takeda
www.nasdaq.com - April 24 at 10:28 AM
BRIEF-Nektar And Takeda To Evaluate Combination Of NKTR-214, A CD122-Biased Agonist, And Tak-659, In Liquid And Solid TumorsBRIEF-Nektar And Takeda To Evaluate Combination Of NKTR-214, A CD122-Biased Agonist, And Tak-659, In Liquid And Solid Tumors
www.reuters.com - April 24 at 10:28 AM
Should Vanguard S&P Small-Cap 600 Growth ETF (VIOG) Be on Your Investing Radar?Should Vanguard S&P Small-Cap 600 Growth ETF (VIOG) Be on Your Investing Radar?
finance.yahoo.com - April 24 at 10:28 AM

SEC Filings

Nektar Therapeutics (NASDAQ:NKTR) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Nektar Therapeutics (NASDAQ:NKTR) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Nektar Therapeutics (NASDAQ NKTR) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.